Skip to content

Frontiers in Pharmacology

ISSN 1663-9812

170 papers in the library · 6,125 citations · publishing 2012-2026

Papers

Sort Most recent Most cited

Aromatic Bromination Abolishes the Psychomotor Features and Pro-social Responses of MDMA ("Ecstasy") in Rats and Preserves Affinity for the Serotonin Transporter (SERT).

Frontiers in Pharmacology February 28, 2019 Patricio Sáez-briones, Vicente Castro-Castillo, Gabriela Díaz-véliz et al. 4 citations

The entactogen MDMA (3,4-methylenedioxy-methamphetamine, “Ecstasy”) exerts its psychotropic effects acting primarily as a substrate of the serotonin transporter (SERT) to induce a non-exocytotic release of serotonin. Nevertheless, the roles of specific positions of the aromatic ring of MDMA associated with the modulation of typical entactogenic effects, using analogs derived from the MDMA...

Ibogaine Administration Modifies GDNF and BDNF Expression in Brain Regions Involved in Mesocorticolimbic and Nigral Dopaminergic Circuits.

Frontiers in Pharmacology 2019 Soledad Marton, Bruno González, Sebastián Rodríguez-bottero et al. 71 citations

Ibogaine is an atypical psychedelic alkaloid, which has been subject of research due to its reported ability to attenuate drug-seeking behavior. Recent work has suggested that ibogaine effects on alcohol self-administration in rats are related to the release of Glial cell Derived Neurotrophic Factor (GDNF) in the Ventral Tegmental Area (VTA), a mesencephalic region which hosts the soma of...

Neurochemical and Behavioral Profiling in Male and Female Rats of the Psychedelic Agent 25I-NBOMe.

Frontiers in Pharmacology 2019 Cristina Miliano, Matteo Marti, Nicholas Pintori et al.

4-Iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (25I-NBOMe), commonly called "N-Bomb," is a synthetic phenethylamine with psychedelic and entactogenic effects; it was available on the Internet both as a legal alternative to lysergic acid diethylamide (LSD) and as a surrogate of 3,4-methylenedioxy-methamphetamine (MDMA), but now it has been scheduled among controlled substances. 25I-NBOMe...

Predicting Responses to Psychedelics: A Prospective Study

Frontiers in Pharmacology November 2, 2018 Adam Hampshire, Christopher Timmermann, Christopher Timmermann et al. 422 citations

Responses to psychedelics are notoriously difficult to predict, yet significant work is currently underway to assess their therapeutic potential and the level of interest in psychedelics among the general public appears to be increasing. We aimed to collect prospective data in order to improve our ability to predict acute- and longer-term responses to psychedelics. Individuals who planned to...

DOI: 10.3389/fphar.2018.00897 (opens in new tab) Psychedelic outcomes Psychological well-being Predictive factors

LSD Administered as a Single Dose Reduces Alcohol Consumption in C57BL/6J Mice

Frontiers in Pharmacology August 31, 2018 Kenneth Alper, Bin Dong, Relish Shah et al. 37 citations

There is a substantive clinical literature on classical hallucinogens, most commonly lysergic acid diethylamide (LSD) for the treatment of alcohol use disorder. However, there has been no published research on the effect of LSD on alcohol consumption in animals. This study evaluated the effect of LSD in mice using a two-bottle choice alcohol drinking paradigm. Adult male C57BL/6J mice were...

Long-Term Stress and Concomitant Marijuana Smoke Exposure Affect Physiology, Behavior and Adult Hippocampal Neurogenesis

Frontiers in Pharmacology July 23, 2018 Kitti Rusznák, Kata Csekő, Zsófia Varga et al. 23 citations

Marijuana is a widely used recreational drug with increasing legalization worldwide for medical purposes. Most experimental studies use either synthetic or plant-derived cannabinoids to investigate the effect of cannabinoids on anxiety and cognitive functions. The aim of this study was to mimic real life situations where young people smoke cannabis regularly to relax from everyday stress....

Safety Profile and Neurocognitive Function Following Acute 4-Fluoroamphetamine (4-FA) Administration in Humans

Frontiers in Pharmacology July 6, 2018 Elizabeth B. de Sousa Fernandes Perna, Eef L. Theunissen, Patrick C. Dolder et al. 18 citations

Availability of novel psychoactive substances (NPS) exponentially increased over the last years. Risk evaluations of NPS are hampered by the lack of pharmacological studies in humans on health parameters. The aim of the present study was Tto evaluate safety and neurocognitive function of healthy volunteers (N=12) who received single doses of 100 and 150 mg 4-fluoroamphetamine (4-FA), a...

DOI: 10.3389/fphar.2018.00713 (opens in new tab) Neurocognitive Administration probate law Pharmacology Function biology +3

Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development

Frontiers in Pharmacology July 5, 2018 Eduardo Ekman Schenberg 242 citations

Mental disorders are rising while development of novel psychiatric medications is declining. This stall in innovation has also been linked with intense debates on the current diagnostics and explanations for mental disorders, together constituting a paradigmatic crisis. A radical innovation is psychedelic-assisted psychotherapy (PAP): professionally supervised use of ketamine, MDMA, psilocybin,...

Ayahuasca and Its DMT- and β-carbolines – Containing Ingredients Block the Expression of Ethanol-Induced Conditioned Place Preference in Mice: Role of the Treatment Environment

Frontiers in Pharmacology May 29, 2018 Elisangela Gouveia Cata-Preta, Yasmim A. Serra, Eliseu Da Cruz Moreira-Junior et al. 50 citations

Ayahuasca is a hallucinogenic beverage produced from the decoction of Banisteriopsis caapi (Bc) and Psychotria viridis (Pv), β-carboline- and N,N-dimethyltryptamine(DMT)-containing plants, respectively. Accumulating evidence suggests that ayahuasca may have therapeutic effects on ethanol abuse. It is not known, however, whether its effects are dependent on the presence of DMT or if...

DOI: 10.3389/fphar.2018.00561 (opens in new tab) Ayahuasca Conditioned place preference Ethanol Pharmacology +4

Hypothesis: The Psychedelic Ayahuasca Heals Traumatic Memories via a Sigma 1 Receptor-Mediated Epigenetic-Mnemonic Process

Frontiers in Pharmacology April 5, 2018 Antonio Inserra 91 citations

Ayahuasca ingestion modulates brain activity, neurotransmission, gene expression and epigenetic regulation. N,N-Dimethyltryptamine (DMT, one of the alkaloids in Ayahuasca) activates sigma 1 receptor (SIGMAR1) and others. SIGMAR1 is a multi-faceted stress-responsive receptor which promotes cell survival, neuroprotection, neuroplasticity, and neuroimmunomodulation. Simultaneously, monoamine...

DOI: 10.3389/fphar.2018.00330 (opens in new tab) Ayahuasca Memory consolidation Traumatic memories

Individual Experiences in Four Cancer Patients Following Psilocybin-Assisted Psychotherapy

Frontiers in Pharmacology April 3, 2018 Tara C. Malone, Sarah E. Mennenga, Jeffrey Guss et al. 128 citations

A growing body of evidence shows that existential and spiritual well-being in cancer patients is associated with better medical outcomes, improved quality of life, and serves as a buffer against depression, hopelessness, and desire for hastened death. Historical and recent research suggests a role for psilocybin-assisted psychotherapy in treating cancer-related anxiety and depression. A...

DOI: 10.3389/fphar.2018.00256 (opens in new tab) Psilocybin Psychotherapist Hallucinogen Clinical psychology +2

Four Weekly Ayahuasca Sessions Lead to Increases in “Acceptance” Capacities: A Comparison Study With a Standard 8-Week Mindfulness Training Program

Frontiers in Pharmacology March 20, 2018 Joaquim Soler, Matilde Elices, Elisabet Domínguez‐clavé et al. 104 citations

Background: The therapeutic effects of the Amazonian plant tea ayahuasca may relate to its ability to enhance mindfulness capacities. Ayahuasca induces a modified state of awareness through the combined action of its active principles: the psychedelic N,N- dimethyltryptamine (DMT) and a series of centrally acting β-carbolines, mainly harmine and tetrahydroharmine. To better understand the...

Metabotropic Glutamate2 Receptors Play a Key Role in Modulating Head Twitches Induced by a Serotonergic Hallucinogen in Mice

Frontiers in Pharmacology March 15, 2018 Mark J. Benvenga, Stephen F. Chaney, Melvyn Baez et al. 26 citations

There is substantial evidence that glutamate can modulate the effects of 5-hydroxytryptamine2A (5-HT2A) receptor activation through stimulation of metabotropic glutamate 2/3 (mGlu2/3) receptors in the prefrontal cortex. Here we show that constitutive deletion of the mGlu2 gene profoundly attenuates an effect of 5-HT2A receptor activation using the mouse head twitch response (HTR). MGlu2 and...

Acute Pharmacological Effects of 2C-B in Humans: An Observational Study

Frontiers in Pharmacology March 13, 2018 Esther Papaseit, Marta Torrens, Mireia Ventura et al. 61 citations

2,5-dimethoxy-4-bromophenethylamine (2C-B) is a psychedelic phenylethylamine derivative, structurally similar to mescaline. It is a serotonin 5-hydroxytryptamine-2A (5-HT2A), 5-hydroxytryptamine-2B (5-HT2B), and 5-hydroxytryptamine-2C (5-HT2C) receptor partial agonist used recreationally as a new psychoactive substance. It has been reported that 2C-B induces mild psychedelic effects, although...

DOI: 10.3389/fphar.2018.00206 (opens in new tab) Mescaline Euphoriant Heart rate Hallucinogen +7

Unifying Theories of Psychedelic Drug Effects

Frontiers in Pharmacology March 2, 2018 Link Swanson 185 citations

How do psychedelic drugs produce their characteristic range of acute effects in perception, emotion, cognition, and sense of self? How do these effects relate to the clinical efficacy of psychedelic-assisted therapies? Efforts to understand psychedelic phenomena date back more than a century in Western science. In this article I review theories of psychedelic drug effects and highlight key...

DOI: 10.3389/fphar.2018.00172 (opens in new tab) Cognitive science Perception Cognition Cognitive psychology

Neuroendocrine Associations Underlying the Persistent Therapeutic Effects of Classic Serotonergic Psychedelics.

Frontiers in Pharmacology March 1, 2018 Emmanuelle A. D. Schindler, Ryan M Wallace, Jordan Sloshower et al.

Recent reports on the effects of psychedelic-assisted therapies for mood disorders and addiction, as well as the effects of psychedelics in the treatment of cluster headache, have demonstrated promising therapeutic results. In addition, the beneficial effects appear to persist well after limited exposure to the drugs, making them particularly appealing as treatments for chronic neuropsychiatric...

The Psychedelic Debriefing in Alcohol Dependence Treatment: Illustrating Key Change Phenomena through Qualitative Content Analysis of Clinical Sessions

Frontiers in Pharmacology February 21, 2018 Elizabeth M. Nielson, Darrick G. May, Alyssa A. Forcehimes et al. 111 citations

Research on the clinical applications of psychedelic-assisted psychotherapy has demonstrated promising early results for treatment of alcohol dependence. Detailed description of the content and methods of psychedelic-assisted psychotherapy, as it is conducted in clinical settings, is scarce. Methods: An open-label pilot (proof-of-concept) study of psilocybin-assisted treatment of alcohol...

DOI: 10.3389/fphar.2018.00132 (opens in new tab) Psilocybin Debriefing Psychotherapist Population +3

Clinical Interpretations of Patient Experience in a Trial of Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder

Frontiers in Pharmacology February 20, 2018 Michael P. Bogenschutz, Samantha K. Podrebarac, Jessie H. Duane et al. 125 citations

After a hiatus of some 40 years, clinical research has resumed on the use of classic hallucinogens to treat addiction. Following completion of a small open-label feasibility study, we are currently conducting a double-blind placebo-controlled clinical trial of psilocybin-assisted treatment of alcohol use disorder. Although treatment effects cannot be analyzed until the study is complete,...

β2-Adrenergic Receptor Activation Suppresses the Rat Phenethylamine Hallucinogen-Induced Head Twitch Response: Hallucinogen-Induced Excitatory Post-synaptic Potentials as a Potential Substrate.

Frontiers in Pharmacology February 8, 2018 Gerard J. Marek, Brian P Ramos

5-Hydroxytryptamine2A (5-HT2A) receptors are enriched in layers I and Va of the rat prefrontal cortex and neocortex and their activation increases the frequency of glutamatergic excitatory postsynaptic potentials/currents (EPSP/Cs) onto layer V pyramidal cells. A number of other G-protein coupled receptors (GPCRs) are also enriched in cortical layers I and Va and either induce (1-adrenergic...

DOI: 10.3389/fphar.2018.00089 (opens in new tab) Full text (opens in new tab) Epinephrine Clenbuterol Ici-118,551 2,5-dimethoxy-4-iodoamphetamine doi

Tolerance and Tachyphylaxis to Head Twitches Induced by the 5-HT2A Agonist 25CN-NBOH in Mice

Frontiers in Pharmacology February 6, 2018 Tobias Buchborn, Taylor Lyons, Thomas Knöpfel 48 citations

The serotonin (5-HT) 2A receptor is the primary molecular target of serotonergic hallucinogens, which trigger large-scale perturbations of the cortex. Our understanding of how 5-HT2A activation may cause the effects of hallucinogens has been hampered by the receptor unselectivity of most of the drugs of this class. Here we used 25CN-NBOH...

Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression

Frontiers in Pharmacology January 17, 2018 Leor Roseman, David Nutt, Robin Carhart-Harris 814 citations

Introduction: It is a basic principle of the "psychedelic" treatment model that the quality of the acute experience mediates long-term improvements in mental health. In the present paper we sought to test this using data from a clinical trial assessing psilocybin for treatment-resistant depression (TRD). In line with previous reports, we hypothesized that the occurrence and magnitude of Oceanic...

The Grass Might Be Greener: Medical Marijuana Patients Exhibit Altered Brain Activity and Improved Executive Function after 3 Months of Treatment

Frontiers in Pharmacology January 17, 2018 Staci A Gruber, Kelly A. Sagar, M. Dahlgren et al.

The vast majority of states have enacted full or partial medical marijuana (MMJ) programs, causing the number of patients seeking certification for MMJ use to increase dramatically in recent years. Despite increased use of MMJ across the nation, no studies thus far have examined the specific impact of MMJ on cognitive function and related brain activation. In the present study, MMJ patients...

S-Ketamine Mediates Its Acute and Sustained Antidepressant-Like Activity through a 5-HT1B Receptor Dependent Mechanism in a Genetic Rat Model of Depression

Frontiers in Pharmacology January 15, 2018 Kristian Du Jardin, Nico Liebenberg, M. Cajina et al.

Rationale: The mechanisms responsible for the unique antidepressant properties of ketamine have only been partly resolved. Recent preclinical reports implicate the neurotransmitter serotonin [5-hydroxytryptamine (5-HT)] in the antidepressant-like response of ketamine, and modulation of 5-HT1B receptors has been hypothesized to attain an important role. Objectives: To evaluate the role of...

Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence: Clinical Observations and Treatment Outcomes.

Frontiers in Pharmacology 2018 Deborah C. Mash, Linda Duque, Bryan Page et al. 109 citations

Ibogaine may be effective for transitioning opioid and cocaine dependent individuals to sobriety. American and European self-help groups provided public testimonials that ibogaine alleviated drug craving and opioid withdrawal symptoms after only a single dose administration. Preclinical studies in animal models of addiction have provided proof-of-concept evidence in support of these claims....

DOI: 10.3389/fphar.2018.00529 (opens in new tab) Full text (opens in new tab) Noribogaine Detoxification Opioid dependence Ibogaine therapy: ibogaine +4

Ibogaine Acute Administration in Rats Promotes Wakefulness, Long-Lasting REM Sleep Suppression, and a Distinctive Motor Profile.

Frontiers in Pharmacology 2018 Joaquín González, José P Prieto, Paola Rodríguez et al. 31 citations

Ibogaine is a potent psychedelic alkaloid that has been the focus of intense research because of its intriguing anti-addictive properties. According to anecdotic reports, ibogaine has been originally classified as an oneirogenic psychedelic; i.e., induces a dream-like cognitive activity while awake. However, the effects of ibogaine administration on wakefulness (W) and sleep have not been...

DOI: 10.3389/fphar.2018.00374 (opens in new tab) Full text (opens in new tab) Rem sleep Hallucinogens Psychedelics Ibogaine: ibogaine +7